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Abstract 
Introduction: Preoperative chemoradiotherapy (CRT), followed by total mesorectal excision, has become the 
standard of care for patients with clinical stages II and III rectal cancer. Patients with pathologic complete response 
(pCR) to preoperative CRT have been reported to have better outcomes than those without pCR. However, the factors 
that predict the response to neoadjuvant CRT have not been well defined. In this study, we aimed to investigate the 
impact of clinical parameters on the development of pCR after neoadjuvant chemoradiation for rectal cancer.
Methods: A total of 323 consecutive patients from a single institution who had clinical stage II or III rectal cancer and 
underwent a long‑course neoadjuvant CRT, followed by curative surgery, between 2005 and 2013 were included. 
Patients were divided into two groups according to their responses to neoadjuvant therapy: the pCR and non‑pCR 
groups. The clinical parameters were analyzed by univariate and multivariate analyses, with pCR as the dependent 
variable.
Results: Of the 323 patients, 75 (23.2%) achieved pCR. The two groups were comparable in terms of age, sex, body 
mass index, tumor stage, tumor location, tumor differentiation, radiation dose, and chemotherapy regimen. On 
multivariate analysis, a pretreatment carcinoembryonic antigen (CEA) level of ≤5 ng/mL [odds ratio (OR) = 2.170, 95% 
confidence interval (CI) = 1.195–3.939, P = 0.011] and an interval of >7 weeks between the completion of chemo‑
radiation and surgical resection (OR = 2.588, 95% CI = 1.484–4.512, P = 0.001) were significantly associated with an 
increased rate of pCR.
Conclusions: The pretreatment CEA level and neoadjuvant chemoradiotherapy‑surgery interval were independent 
clinical predictors for achieving pCR. These results may help clinicians predict the prognosis of patients and develop 
adaptive treatment strategies.
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Background
Preoperative chemoradiotherapy (CRT), followed by total 
mesorectal excision (TME), has become the standard 
of care for patients with clinical stages II and III rectal 
cancer [1, 2]. Compared with surgical resection alone 
or postoperative CRT, preoperative CRT improves local 
control and increases the rate of sphincter preservation 
[3, 4]. However, the response to neoadjuvant CRT var-
ies among different individuals. Most patients respond 
to neoadjuvant CRT, and approximately 10%–30% of 
patients achieve a pathologic complete response (pCR), 
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wherein they lack any viable tumor cells in the final sur-
gical specimen [5]. By contrast, some patients show no 
response or are resistant to CRT. It has been well docu-
mented that patients who achieved pCR had better long-
term outcomes than those without pCR [5–8]. Moreover, 
a wait-and-see policy is safe and feasible for patients with 
clinical complete response to neoadjuvant CRT [9, 10].
As patients with pCR have a better prognosis, 
and the treatment strategy for these patients may be 
entirely different from that for the patients without 
pCR, the ability to predict the response to neoadjuvant 
CRT is of great clinical importance. Nevertheless, the 
factors that predict patient response to neoadjuvant 
CRT for rectal cancer have not been well defined. Sev-
eral small retrospective studies have identified some 
clinical factors and molecular biomarkers that are 
predictors of tumor response to preoperative CRT, 
including the tumor size, carcinoembryonic antigen 
(CEA) level, epidermal growth factor receptor, and p21 
[11–13]. These studies had small sample sizes of 
patients with pCR and investigated different response 
levels. Consequently, it remains a great challenge for 
clinicians to predict pCR after neoadjuvant CRT for 
rectal cancer.
In this study, we evaluated a large number of patients 
with pCR and aimed to indentify clinical factors or treat-
ment variables associated with complete response to pre-
operative CRT for rectal cancer.
Patients and methods
Patient selection
This study was approved by the ethics committee at 
Cancer Hospital, Chinese Academy of Medical Sci-
ences, and the protocol conformed to the ethical guide-
lines of the 1975 Declaration of Helsinki. A total of 348 
consecutive patients who underwent neoadjuvant CRT 
between January 2005 and December 2013 were iden-
tified from our prospectively entered database. The 
criteria for neoadjuvant CRT were as follows: rectal 
adenocarcinoma confirmed by pathology, clinical stages 
II and III tumors, and tumors located within 10  cm of 
the anal verge. Twenty-five patients were excluded from 
the study for the following reasons: 2 patients refused 
surgery, 16 were treated with neoadjuvant radiotherapy 
without chemotherapy, and 7 underwent surgery at 
other hospitals.
Evaluation
All patients underwent colonoscopy with biopsy and 
were histologically diagnosed with adenocarcinoma. 
Preoperative clinical staging was determined by abdomi-
nal and pelvic computed tomography (CT), transrectal 
ultrasonography, pelvic magnetic resonance imaging, or 
a combination of these.
At least two pathologists, who are specialized in colo-
rectal cancer, assessed the surgical specimens. pCR was 
defined as the absence of viable tumor cells in the surgi-
cal specimen, including lymph nodes. Patients without 
pCR were grouped into the non-pCR cohort.
Treatment
As previously reported [14, 15], all patients planned to 
undergo a total irradiation dose of 50.0  Gy to the pel-
vic area, delivered in 2.0-Gy fractions daily, five times 
per week for 5 weeks. One of the two chemotherapeutic 
regimens was delivered concurrently with radiotherapy 
as follows: oral capecitabine at a dose of 1,650  mg/m2 
per day for 35  days, without weekend breaks, or oral 
capecitabine at a dose of 1,650 mg/m2 per day for 35 days 
plus intravenous oxaliplatin at a dose of 50 mg/m2 once 
weekly for 5  weeks. Surgical resection was planned for 
6–8  weeks after the completion of preoperative CRT, 
irrespective of the response to CRT. TME was performed 
for each patient.
Data collection
The following data were reviewed in our database: sex, 
age, body mass index (BMI), clinical TNM classifica-
tion, tumor differentiation, tumor distance from the anal 
verge, radiation dose, pretreatment serum CEA level, 
chemotherapy regimen, and the interval between CRT 
and surgery.
Statistical analysis
Nonparametric variables are presented as the median 
and range, and categorical variables are presented as the 
frequency with percentages. Continuous variables were 
analyzed with the Mann–Whitney U test, and categori-
cal variables were analyzed with the Chi square test or 
Fisher’s exact test, when appropriate. Univariate and 
multivariate analyses were performed by using logistic 
regression and Cox proportional hazard ratios to identify 
factors that predict pCR. All statistical tests were two-
sided, and a P value of <0.05 was considered statistically 
significant. Data were analyzed by Statistical Package for 




Patient demographics and tumor characteristics are 
shown in Table  1. A total of 323 consecutive patients 
with clinical stages II and III rectal adenocarcinoma 
who underwent long-course neoadjuvant CRT followed 
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by TME were included in this study. The median age 
was 57  years (range 26–86  years). Of the 323 patients, 
174 (53.9%) were males, and 149 (46.1%) were females; 
78 (27.2%) had clinical stage II disease, and 235 (72.8%) 
had clinical stage III disease. The median distance of the 
tumor from the anal verge was 6 cm (range 0–10 cm). All 
patients received a long-course radiation, and the median 
radiation dose was 50  Gy (range 38–60  Gy). A total of 
267 (82.7%) patients received oral capecitabine alone, 
concurrent with radiotherapy, and 56 (17.3%) patients 
received both capecitabine and oxaliplatin. The median 
interval between the completion of CRT and surgery was 
50 days (range 25–105 days).
Of the 323 patients, 75 (23.2%) achieved a pCR, and 
248 (76.8%) did not. The patients were divided into two 
groups, the pCR (n = 75) and non-pCR (n = 248) groups. 
The following clinical parameters were comparable 
between the pCR and non-pCR groups: age, sex, BMI, 
distance of the tumor from the anal verge, pretreatment 
clinical T or N category, and tumor differentiation. The 
chemotherapy regimens, radiation dose, and type of sur-
gery were not significantly different between the pCR 
and non-pCR groups. The pretreatment serum CEA level 
was significantly lower in the pCR group than in the non-
pCR group (2.9 vs. 4.2  ng/mL, P =  0.001). The median 
interval between the completion of CRT and surgery was 
Table 1 Patient demographics and tumor characteristics
BMI body mass index, CEA carcinoembryonic antigen, pCR pathologic complete response, cT category clinical tumor category, cN category clinical node category, cTNM 
classification clinical tumor-node-metastasis classification.
a These values are presented as the median followed by the range in parentheses; other values are presents as numbers of patients followed by the percentage in 
parentheses.
Variable Total (n = 323) pCR (n = 75) Non-pCR (n = 248) P value
Age (years)a 57 (26–86) 57 (26–86) 58 (32–78) 0.773
Sex 0.342
 Male 174 (53.9) 44 (58.7) 130 (52.4)
 Female 149 (46.1) 31 (41.3) 118 (47.6)
BMI (kg/m2)a 23.6 (17.0–32.2) 24.2 (17.4–31.2) 23.5 (17.0–32.2) 0.386
cT category 0.297
 2 26 (8.0) 7 (9.3) 19 (7.6)
 3 234 (72.5) 58 (77.3) 176 (71.0)
 4 63 (19.5) 10 (13.3) 53 (21.4)
cN category 0.791
 N0 88 (27.2) 21 (28.0) 67 (27.0)
 N1 161 (49.9) 35 (46.7) 126 (50.8)
 N2 74 (22.9) 19 (25.3) 55 (22.2)
cTNM classification 0.867
 II 88 (27.2) 21 (28.0) 67 (27.0)
 III 235 (72.8) 54 (72.0) 181 (73.0)
Distance from the anal verge (cm)a 6 (0–10) 6 (0–10) 6 (0–10) 0.721
Pretreatment CEA (ng/mL)a 3.8 (0.02–31.5) 2.9 (0.06–24.9) 4.2 (0.02–31.5) 0.001
Tumor differentiation 0.679
 Well 24 (7.4) 6 (8.0) 18 (7.3)
 Moderate 250 (77.4) 60 (80.0) 190 (76.6)
 Poor 49 (15.2) 9 (12.0) 40 (16.1)
Type of surgery 0.543
 Low anterior resection 190 (58.8) 40 (53.3) 150 (60.5)
 Abdominoperineal resection 122 (37.8) 32 (42.7) 90 (36.3)
 Hartmann operation 11 (3.4) 3 (4.0) 8 (3.2)
Chemotherapy 0.729
 Capecitabine 267 (82.7) 61 (81.3) 206 (83.1)
 Capecitabine + oxaliplatin 56 (17.3) 14 (18.7) 42 (16.9)
Time interval (day)a 50 (25–105) 57 (35–79) 49 (25–105) <0.001
Radiation dose (Gy)a 50 (38–60) 50 (40–60) 50 (38–60) 0.225
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significantly longer in the pCR group than in the non-
pCR group (57 vs. 49 days, P < 0.001).
Predictive factors of pCR
For the univariate and multivariate analyses, the variables 
were analyzed as discrete categorical variables. A median 
age of 57 was chosen as the cut-off value. We chose to 
investigate tumors located within 5 cm of the anal verge 
because that criterion could distinguish between middle 
and lower rectal cancer. An interval from the comple-
tion of CRT to surgery of longer than 7 weeks was chosen 
because it was the median interval in our study.
On univariate analysis, an interval from the completion 
of chemoradiation to surgery of >7 weeks was associated 
with an increased rate of pCR [odds ratio (OR) = 2.658, 
95% confidence interval (CI) = 1.484–4.512, P = 0.001]. 
A lower pretreatment serum CEA level (≤5 ng/mL) was 
also significantly associated with an increased rate of 
pCR (OR  =  2.249, 95% CI  =  1.251–4.046, P  =  0.007). 
Other factors, such as age, sex, tumor differentiation, 
clinical TNM classification, tumor distance from the anal 
verge, radiation dose, and chemotherapy regimen, were 
not significantly associated with pCR (Table 2).
On multivariate analysis, a pretreatment CEA level 
of ≤5  ng/mL (OR  =  2.170, 95% CI  =  1.195–3.939, 
P = 0.011) and an interval from the completion of neo-
adjuvant CRT to surgery of >7 weeks (OR = 2.588, 95% 
CI  =  1.484–4.512, P  =  0.001) were identified as inde-
pendent predictors for achieving a pCR (Table 3).
Discussion and conclusions
In this study, we analyzed clinical factors or treatment 
variables that are associated with a complete response 
to preoperative CRT. Our univariate and multivariate 
analysis results showed that a pretreatment CEA level of 
≤5 ng/mL and an interval from the completion of neo-
adjuvant CRT to surgery of >7  weeks were significantly 
associated with an increased rate of pCR.
Few studies have evaluated clinical factors associ-
ated with complete response to preoperative CRT for 
rectal cancer [16–20]. García-Aguilar et  al. [16] studied 
the clinical factors of 168 patients with locally advanced 
rectal cancer, but the authors failed to find any factors 
that were associated with pCR. Kalady et  al. [17] iden-
tified that an interval of >8 weeks between the comple-
tion of preoperative CRT and surgical resection was the 
only predictor for pCR in a retrospective review of 242 
patients. In the largest sample size study to date, Das 
et al. [18] evaluated the predictors of pCR in 562 patients 
and found that the circumferential tumor extent was 
the only factor that was significantly associated with 
pCR. In a group of 249 patients assessed by Park et  al. 
[19], the pre-CRT movability, post-CRT size, post-CRT 
morphology, and gross change were independent predic-
tors of pCR. More recently, Garland et al. [20] found that 
the tumor size and pretreatment clinical N category were 
independent predictors of pCR after evaluating the clini-
cal factors of 297 patients.
The serum CEA level is widely used as a tumor marker 
in patients with colorectal cancer. The pretreatment CEA 
level is useful for assessing the prognosis, and postopera-
tive CEA testing is used for the early detection of recur-
rent disease [21]. However, few studies have evaluated 
the value of the CEA level in predicting the response to 
preoperative CRT. We found that the CEA level was sig-
nificantly higher in the non-pCR group than in the pCR 
group; 76.0% of the patients with a pCR had a normal 
pretreatment CEA level, versus 58.5% of the patients in 
the non-pCR group. In addition, a normal pretreatment 
CEA level was significantly associated with pCR in both 
univariate and multivariate analyses. Several previous 
studies have reported similar results [20, 22, 23]. Yoon 
et al. [22] found that the pretreatment CEA level was an 
independent predictor for pCR. Recently, Garland et  al. 
[20] identified that the pretreatment serum CEA levels 
and a decrease in the pre- to post-treatment serum CEA 
level were significantly associated with pCR in univariate 
analysis. Additionally, tumor cells that have a high den-
sity of CEA may resist radiation [24]. However, the exact 
mechanism is unclear and remains to be elucidated.
Radiation-induced necrosis and subsequent tumor 
regression is a time-dependent phenomenon in which 
a longer interval between the completion of CRT and 
surgery may increase the rate of pCR [17]. In this 
study, we found that an interval of >7  weeks between 
the completion of CRT and surgical resection was sig-
nificantly associated with a higher rate of pCR (31.3 vs. 
14.6%, P =  0.001). Similarly, Kalady et  al. [17] reported 
that an interval of >8  weeks was the only independ-
ent predictor for pCR (OR = 2.63, 95% CI = 1.13–6.12, 
P = 0.020). Wolthuis et al. [25] reported that an interval 
of >7  weeks was associated with increased pCR (28 vs. 
16%, P = 0.030), and the 5-year cancer-specific survival 
rate was higher in the long-interval group than in the 
short-interval group (91 vs. 83%, P = 0.046). Conversely, 
Stein et  al. [26] and Lim et  al. [27] did not find that a 
longer interval between CRT and surgical resection was 
an independent predictor of pCR. To settle these disputes 
about the optimal time from CRT to surgery, randomized 
controlled trials are needed.
Increasing data indicate that the treatment response 
to chemoradiation associated with the oncologic out-
comes [28]. To improve the response, some randomized 
trials have added oxaliplatin or targeted drugs into the 
currently widely used fluorinated, pyrimidine-based pre-
operative chemotherapy regimen [29–31]. However, none 
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of these studies reported an increased pCR rate. Recently, 
O’Connell et  al. [29] reported that adding oxaliplatin did 
not improve the rates of pCR, sphincter-sparing surgery, 
or surgical down-staging; instead, oxaliplatin added signifi-
cant toxicity. We also found that the addition of oxaliplatin 
did not increase the pCR rate (25.0 vs. 22.8%, P = 0.729). 
By contrast, waiting a longer time between CRT and sur-
gery was significantly associated with a higher rate of pCR.
There are some potential limitations of this study. 
Because this was a retrospective study, there may be bias. 
Table 2 Univariate analyses of predictors for pCR
All values are presents as numbers of patients followed by percentages in parentheses. Other footnotes as in Table 1.
CI confidence interval.
Variable pCR (n = 75) Non-pCR (n = 248) Odds ratio (95% CI) P value
Age (years)
 ≤57 36 (48.0) 127 (51.2) Reference –
 >57 39 (52.0) 121 (48.8) 1.137 (0.678–1.907) 0.626
Sex
 Male 44 (58.7) 130 (52.4) Reference –
 Female 31 (41.3) 118 (47.6) 0.776 (0.460–1.309) 0.342
cT category
 2 7 (9.3) 19 (7.7) Reference –
 3 58 (77.3) 176 (71.0) 0.894 (0.358–2.236) 0.811
 4 10 (13.3) 53 (21.4) 0.512 (0.171–1.537) 0.233
cN category
 N0 21 (28.0) 67 (27.0) Reference –
 N1 35 (46.7) 126 (50.8) 0.886 (0.478–1.642) 0.701
 N2 19 (25.3) 55 (22.2) 1.102 (0.539–2.255) 0.790
cTNM classification
 II 21 (28.0) 67 (27.0) Reference –
 III 54 (72.0) 181 (73.0) 0.952 (0.535–1.695) 0.867
Distance from the anal verge (cm)
 >5 44 (58.7) 156 (62.9) Reference –
 ≤5 31 (41.3) 92 (37.1) 1.195 (0.705–2.023) 0.508
Pretreatment CEA (ng/mL)
 >5 18 (24.0) 103 (41.5) Reference –
 ≤5 57 (76.0) 145 (58.5) 2.249 (1.251–4.046) 0.007
Tumor differentiation
 Well 6 (8.0) 18 (7.3) Reference –
 Moderate 60 (80.0) 190 (76.6) 0.947 (0.360–2.495) 0.913
 Poor 9 (12.0) 40 (16.1) 0.675 (0.209–2.182) 0.511
Type of surgery
 Low anterior resection 40 (53.3) 150 (60.5) Reference –
 Abdominoperineal resection 32 (42.7) 90 (36.3) 1.333 (0.782–2.273) 0.290
 Hartmann operation 3 (4.0) 8 (3.2) 1.406 (0.357–5.545) 0.626
Chemotherapy
 Capecitabine 61 (81.3) 206 (83.1) Reference –
 Capecitabine + oxaliplatin 14 (18.7) 42 (16.9) 1.126 (0.577–2.198) 0.729
Time interval (weeks)
 ≤7 23 (30.7) 134 (54.0) Reference –
 >7 52 (69.3) 114 (46.0) 2.658 (1.532–4.609) 0.001
Radiation dose (Gy)
 <50 4 (5.3) 14 (5.6) Reference –
 =50 63 (84.0) 221(89.1) 0.998 (0.317–3.138) 0.997
 >50 8 (10.7) 13 (5.2) 2.154 (0.522–8.892) 0.289
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Additionally, we evaluated patients who were treated 
over the course of 9 years. The CRT regimen and path-
ologic assessment may change over time. Other studies 
have reported some variables that were not included in 
this study, such as tumor size, circumferential extent of 
tumor, morphology, and gross change after CRT. These 
factors are subjective parameters that are susceptible to 
inter-observer variations, and it is difficult to assess these 
factors in a retrospective study.
Further prospective studies are needed to identify the 
predictors for pCR and elucidate its potential mecha-
nisms. In the future, it may be possible to stratify patients 
into different response groups before CRT is initiated, 
which could allow us to develop individualized therapy 
plans. Patients who are considered good responders to 
preoperative CRT may benefit little from TME, and their 
optimal treatment may involve nonoperative manage-
ment or local excision. Patients who are stratified into the 
poor response group may need more aggressive therapies 
or alternative new therapies.
In conclusion, this large, retrospective study demon-
strated that a pretreatment CEA level of ≤5 ng/mL and 
an interval from the completion of neoadjuvant CRT to 
surgery of >7 weeks were independent clinical predictors 
for achieving pCR. These findings may help clinicians 
predict the prognosis of patients and develop individual-
ized treatment strategies.
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